Longview Partners Guernsey LTD Cuts Position in IQVIA Holdings Inc. (NYSE:IQV)

Longview Partners Guernsey LTD trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,152,444 shares of the medical research company’s stock after selling 91,896 shares during the quarter. IQVIA accounts for about 3.2% of Longview Partners Guernsey LTD’s holdings, making the stock its 22nd largest position. Longview Partners Guernsey LTD owned about 1.19% of IQVIA worth $422,977,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Norges Bank purchased a new stake in shares of IQVIA during the 4th quarter valued at $336,041,000. Raymond James Financial Inc. bought a new position in IQVIA during the fourth quarter valued at about $236,120,000. American Century Companies Inc. increased its holdings in IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock worth $222,987,000 after buying an additional 905,960 shares during the last quarter. Invesco Ltd. raised its position in IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock worth $509,012,000 after acquiring an additional 902,226 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Barclays reiterated an “equal weight” rating and issued a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Robert W. Baird cut their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Finally, Morgan Stanley boosted their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $241.50.

IQVIA Stock Down 0.3 %

Shares of NYSE:IQV opened at $148.73 on Thursday. The firm has a market capitalization of $26.22 billion, a PE ratio of 19.83, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88. The firm has a fifty day moving average of $178.83 and a 200 day moving average of $198.11.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.